Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid

被引:6
作者
Dogan, Ismail [1 ]
Kalyoncu, Umut [2 ]
Kilic, Levent [2 ]
Akdogan, Ali [2 ]
Karadag, Omer [2 ]
Kiraz, Sedat [2 ]
Bilgen, Sule A. [2 ]
Ertenli, Ihsan [2 ]
机构
[1] Yildirim Beyazit Univ, Dept Internal Med, Div Rheumatol, Ankara, Turkey
[2] Hacettepe Univ, Dept Internal Med, Div Rheumatol, Ankara, Turkey
关键词
Avascular necrosis; alternate day steroid usage; systemic lupus erythematosus; FEMORAL-HEAD; IDIOPATHIC OSTEONECROSIS; DISEASE-ACTIVITY; BONE NECROSIS; RISK-FACTORS; SLE; CLASSIFICATION; PREVALENCE; CRITERIA; THERAPY;
D O I
10.3906/sag-1908-182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Avascular necrosis (AVN) is the death of bone due to compromise of blood flow. The etiology of AVN is multifactorial; corticosteroid usage is the second most significant factor after trauma, and systemic lupus erythematosus (SLE) is the most common underlying disease. The objective of this study was to assess the factors of AVN in SLE patients. Materials and methods: The study included 127 patients with SLE who fulfilled 1997 American College of Rheumatology (ACR) revised criteria. Demographic data, age at SLE diagnosis, disease duration, disease activity, body mass index, clinical findings, antiphospholipid syndrome, steroid usage, dose and duration, comorbid diseases, and smoking history were recorded. Results: AVN was found in 11 of 127 (8.7%) SLE patients. Hyperlipidemia (P < 0.001), cushingoid body habitus (P < 0.001), and proteinuria (P = 0.013) were found at higher rates in the AVN group. All of the 11 AVN cases had osteoporosis (P < 0.02). In multivariate regression analysis, daily steroid usage was the only factor for development of AVN in SLE. Conclusion: The hypothesis of our study was that an alternate day steroid regimen may decrease AVN frequency in SLE patients.
引用
收藏
页码:219 / 224
页数:6
相关论文
共 50 条
  • [41] Successful treatment using corticosteroid combined antibiotic for acute acalculous cholecystitis patients with systemic lupus erythematosus
    Liu, Wei
    Chen, Weijie
    He, Xiaodong
    Qu, Qiang
    Hong, Tao
    Li, Binglu
    MEDICINE, 2017, 96 (27)
  • [42] Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
    Cheng Cheng
    Can Huang
    Zhen Chen
    Feng Zhan
    Xinwang Duan
    Yongfu Wang
    Cheng Zhao
    Zhenbiao Wu
    Jian Xu
    Hongbin Li
    Min Yang
    Rui Wu
    Jiuliang Zhao
    Shangzhu Zhang
    Qian Wang
    Xiaomei Leng
    Xinping Tian
    Mengtao Li
    Xiaofeng Zeng
    Arthritis Research & Therapy, 25
  • [43] Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
    Cheng, Cheng
    Huang, Can
    Chen, Zhen
    Zhan, Feng
    Duan, Xinwang
    Wang, Yongfu
    Zhao, Cheng
    Wu, Zhenbiao
    Xu, Jian
    Li, Hongbin
    Yang, Min
    Wu, Rui
    Zhao, Jiuliang
    Zhang, Shangzhu
    Wang, Qian
    Leng, Xiaomei
    Tian, Xinping
    Li, Mengtao
    Zeng, Xiaofeng
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [44] Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus
    Hussenbocus, Yoosuf Ali Ashraf Muhammad
    Jin, Ziyi
    Pan, Wenyou
    Liu, Lin
    Wu, Min
    Hu, Huaixia
    Ding, Xiang
    Wei, Hua
    Zou, Yaohong
    Qian, Xian
    Wang, Meimei
    Wu, Jian
    Tao, Juan
    Tan, Jun
    Da, Zhanyun
    Zhang, Miaojia
    Li, Jing
    Feng, Xuebing
    Sun, Lingyun
    CLINICAL RHEUMATOLOGY, 2022, 41 (07) : 2043 - 2052
  • [45] Lymphadenopathy in systemic lupus erythematosus: no microbial trigger found by shotgun metagenomics in a retrospective study on 38 patients
    Papo, Matthias
    Cappy, Pierre
    Degachi, Alexandre
    Woerther, Paul-Louis
    Saal, Caroline
    Charlotte, Frederic
    Brocheriou, Isabelle
    Lhote, Raphael
    Trefond, Ludovic
    Hie, Miguel
    Haroche, Julien
    Pha, Micheline
    Cohen-Aubart, Fleur
    Mathian, Alexis
    Rodriguez, Christophe
    Amoura, Zahir
    RHEUMATOLOGY, 2024,
  • [46] Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
    Griffiths, B
    Mosca, M
    Gordon, C
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (05): : 685 - 708
  • [47] Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies
    Masson, Walter
    Rossi, Emiliano
    Mora-Crespo, Lorena M.
    Cornejo-Pena, Guillermo
    Pessio, Carla
    Gago, Mariela
    Alvarado, Rodolfo N.
    Scolnik, Marina
    CLINICAL RHEUMATOLOGY, 2020, 39 (02) : 455 - 462
  • [48] Non-corticosteroid-related risk factors for osteonecrosis in patients with systemic lupus erythematosus: a meta-analysis
    Wang, Tao
    Li, Zhijun
    Li, Xingfu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (05): : 8085 - 8096
  • [49] Risk of avascular necrosis in patients with inflammatory bowel disease: Insights from a nationwide cohort study and the impact of corticosteroid use
    Moon, Jung Min
    Kwon, Kyoung-Eun
    Lee, Ju Won
    Minn, Kyung Rok
    Kim, Kyuwon
    Seo, Jeongkuk
    Shin, Seung Yong
    Jung, Sun-Young
    Choi, Chang Hwan
    DIGESTIVE AND LIVER DISEASE, 2025, 57 (01) : 176 - 183
  • [50] Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus
    Huang, Shirley P.
    Dersarkissian, Maral
    Gu, Yuqian M.
    Duh, Mei Sheng
    Wang, Min-Jung
    Benson, John
    Vu, Jensen Duy
    Averell, Carlyne M.
    Bell, Christopher F.
    CLINICAL THERAPEUTICS, 2023, 45 (07) : 619 - 626